Company Profile

Ichor Biologics LLC
Profile last edited on: 2/17/2020            CAGE: 7WPU3            UEI: K7HRH5JERRB7

Isolation of human monoclonal antibodies (mAbs), to neutralize emerging/re-emerging infectious diseases
Year Founded
1st Award Year
Latest Award
Program Status
Popularity Index


Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

423W 127th Street
New York, NY 10027
Multiple Locations:   
Congressional District:   13
County:   New York

Public Profile

Ichor Biologics (Ichor) is a pre-clinical biotechnology company having developed a novel platform for the isolation of naturally-occurring human monoclonal antibodies (Abs) against infectious diseases - effectively addressing leveraging natural human resistance to infectious disease. The firm's platform that exploits the evolution of human resistance to infectious diseases by identifying the immunological signatures associated with protection - enabling development of the antibodies that mimic those protective signatures: antibodies can then be used as therapeutics to confer protection in individuals that have succumb to disease states. Management indicate intent to utilize this platform to accelerate therapeutic development in the infectious disease space by rapidly producing Antibody-based therapeutics, which possess high safety and clinical efficacy profiles. The speed and efficacy of the platform will be utilized to produce Antibody-related intellectual property (IP) through the preclinical validation stage. In turn, that IP will be leveraged to establish strategic partnerships or licensing deals to engage industry partners, inturn providing access to clinical trial pipelines. ?

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
2020 1 NIH $355,000
Development of Broadly Neutralizing Antibodies to Treat Hantavirus Infections

Key People / Management

  Raymond Alvarez

  Justin Ring -- Founder

SBIR firms in the news

There are no news available.